We are live on ! Find out more
NMC

NEA Management Company Portfolio holdings

AUM $1.76B
1-Year Est. Return 223.33%
This Fund
S&P 500
This Quarter Est. Return
+6.24%
1 Year Est. Return
+223.33%
3 Year Est. Return
+769.45%
5 Year Est. Return
+668.45%
10 Year Est. Return
+14,843.34%
AUM
$2.13B
AUM Growth
-$114M
Cap. Flow
-$40.3M
Cap. Flow %
-1.89%
Top 10 Hldgs %
71.72%
Holding
45
New
2
Increased
3
Reduced
1
Closed
2

Top Buys

Rank Stock Value
1
SURF
Surface Oncology, Inc. Common Stock
SURF
+$48M
2
LITS
Lite Strategy Inc
LITS
+$17.5M
3
CBIO
Crescent Biopharma
CBIO
+$8.68M
4
ARDX icon
Ardelyx
ARDX
+$5.81M
5
AVEO
AVEO Pharmaceuticals, Inc.
AVEO
+$3.37M

Top Sells

Rank Stock Value
1
CRSP icon
CRISPR Therapeutics
CRSP
+$79.4M
2
IMMU
Immunomedics Inc
IMMU
+$40.5M
3
AQ
Aquantia Corp. Common Stock
AQ
+$3.76M

Sector Composition

Rank Sector Weight
1 Healthcare 94.51%
2 Technology 0.85%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ELGX
26
DELISTED
Endologix Inc
ELGX
$14.1M 0.66%
249,020
– –
ARQL
27
DELISTED
Arqule Inc
ARQL
$13.9M 0.65%
2,520,316
– –
NITE
28
DELISTED
Nightstar Therapeutics plc American Depositary Shares
NITE
$11.4M 0.54%
714,285
– –
CSBR icon
29
Champions Oncology
CSBR
$74.5M
$9.91M 0.46%
1,562,500
– –
TCON
30
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
$9.36M 0.44%
17,336
– –
DZSI
31
DELISTED
DZS Inc. Common Stock
DZSI
$9.33M 0.44%
956,255
– –
RIGL icon
32
Rigel Pharmaceuticals
RIGL
$681M
$9.18M 0.43%
324,315
– –
AFMD
33
DELISTED
Affimed
AFMD
$8.48M 0.4%
513,889
– –
TRIL
34
DELISTED
Trillium Therapeutics Inc.
TRIL
$7.5M 0.35%
1,250,000
– –
MDB icon
35
MongoDB
MDB
$27.1B
$7.45M 0.35%
150,000
– –
XFOR icon
36
X4 Pharmaceuticals
XFOR
$375M
$7.26M 0.34%
11,111
– –
RGLS
37
DELISTED
Regulus Therapeutics
RGLS
$7.24M 0.34%
91,583
– –
PHXM
38
DELISTED
PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
$6.98M 0.33%
62,500
– –
TRVN
39
DELISTED
Trevena, Inc.
TRVN
$5.49M 0.26%
6,099
– –
VIRX
40
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$2.75M 0.13%
37,094
– –
TNTR
41
DELISTED
Tintri, Inc. Common Stock
TNTR
$1.3M 0.06%
5,253,358
– –
AKTX
42
Akari Therapeutics
AKTX
$13.8M
$882K 0.04%
565
– –
AYTU icon
43
AYTU BioPharma
AYTU
$23.9M
$12K ﹤0.01%
11
– –
IMMU
44
DELISTED
Immunomedics Inc
IMMU
– –
-2,772,643
Closed -$40.5M
AQ
45
DELISTED
Aquantia Corp. Common Stock
AQ
– –
-239,587
Closed -$3.76M
1
2

Similar funds

NM
NWI Management New York $1.76B AUM 45.08% 1-Year Est. Return
SLF
Sun Life Financial Toronto, Ontario, Canada $1.76B AUM 19.57% 1-Year Est. Return
CCIA
Campbell & Co Investment Adviser Baltimore, Maryland $1.76B AUM 13.06% 1-Year Est. Return
SW
Simplicity Wealth Summit, New Jersey $1.76B AUM 20.49% 1-Year Est. Return
CGH
Contrarius Group Holdings Hamilton, Bermuda $1.77B AUM 83.15% 1-Year Est. Return
PWP
Principle Wealth Partners Madison, Connecticut $1.75B AUM 21.63% 1-Year Est. Return
CIP
CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return
GD
Grandfield & Dodd New York $1.77B AUM 23.43% 1-Year Est. Return

NEA Management Company's Q2 2018 Portfolio in Review

As of Q2 2018, NEA Management Company held 45 positions worth $2.13B, down 5.1% from $2.25B the previous quarter. Its ten largest holdings account for 72% of the portfolio.

NEA Management Company's Q2 2018 filing shows 2 new, 3 increased, 1 reduced and 2 closed positions. Its largest new stake was Surface Oncology, Inc. Common Stock: 3,315,149 shares worth $54.1M. The largest sale was CRISPR Therapeutics, an estimated $79.4M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 92% a quarter earlier, followed by Technology.

  • NEA Management Company's largest Q2 2018 buy was Surface Oncology, Inc. Common Stock: 3,315,149 shares worth $54.1M.
  • NEA Management Company added most to Crescent Biopharma in Q2 2018, an estimated $8.68M increase.
  • NEA Management Company's biggest Q2 2018 reduction was CRISPR Therapeutics, cutting an estimated $79.4M.
  • NEA Management Company fully exited Immunomedics Inc in Q2 2018, selling an estimated $40.5M.
  • NEA Management Company's ten largest holdings make up 72% of its $2.13B portfolio in Q2 2018.
  • NEA Management Company opened 2 new positions and closed 2 in Q2 2018.
  • NEA Management Company's portfolio value fell 5.1% quarter-over-quarter to $2.13B.

Based on NEA Management Company's 13F filing for Q2 2018, filed 9 Aug 2018.